**Abstracts**

**TP022/#997**

**SENTEIN-NODE BIOPSY IN EARLY STAGE OVARIAN CANCER: PRELIMINARY RESULTS OF A PROSPECTIVE MULTICENTRE STUDY (SELY)**

1Camilla Nero, 1Nicolò Bizzani, 1Stefano Di Berardino, 1Francesca Silano, 2Giuseppe Vizzielli, 3Francesco Cosenzino, 4Virginia Vargiu, 4Pierandrea De Iaco, 5Myriam Perrone, 6Enrico Villa, 7Stefano Uccella, 1Fabio Ghezzi, 1Luigi Carlo Turco, 1Giacomo Corrado, 1Diana Giannarelli, 1Tina Pasciuto, 1Anna Fagotti, 1Giovanni Scambia.

1Department of Gynecology, Shenyang, China
2Department of Gynecology, Medical University, Shanghai, China
3University of Udine, Gynecologic Oncology, Udine, Italy
4University of Bologna, Obstetrics and Gynecology, Bologna, Italy
5Istituto Nazionale Tumori Regina Elena-IFO, Gynecologic Oncology, Rome, Italy
6AOUI-Università di Verona, Gynecologic Oncology, Verona, Italy
7University of Insubria, Gynecologic Oncology Unit, Varese, Italy
8University of Milano, Department of Gynecologic Oncology, Milan, Italy
9University of Bologna, Obstetrics and Gynecology, Bologna, Italy
10European Institute of Oncology, Milan, Italy
11University of Florence, Department of Obstetrics and Gynecology, Lucca, Italy
12University of Pisa, Department of Obstetrics and Gynecology, Pisa, Italy
13National University of Singapore, Department of Obstetrics and Gynecology, Singapore, Republic of
14Hospital of Turin, Department of Obstetrics and Gynecology, Turin, Italy
15University of Torino, Department of Obstetrics and Gynecology, Torino, Italy
16University of Verona, Department of Obstetrics and Gynecology, Verona, Italy
17University of Insubria, Gynecologic Oncology Unit, Varese, Italy
18University of Milan, Department of Gynecology, Milan, Italy
19University of Florence, Department of Obstetrics and Gynecology, Lucca, Italy
20University of Pisa, Department of Obstetrics and Gynecology, Pisa, Italy
21National University of Singapore, Department of Obstetrics and Gynecology, Singapore, Republic of
22Hospital of Turin, Department of Obstetrics and Gynecology, Turin, Italy
23University of Verona, Department of Obstetrics and Gynecology, Verona, Italy
24University of Insubria, Gynecologic Oncology Unit, Varese, Italy
25European Institute of Oncology, Milan, Italy
26University of Florence, Department of Obstetrics and Gynecology, Lucca, Italy
27University of Pisa, Department of Obstetrics and Gynecology, Pisa, Italy
28National University of Singapore, Department of Obstetrics and Gynecology, Singapore, Republic of
29Hospital of Turin, Department of Obstetrics and Gynecology, Turin, Italy
30University of Verona, Department of Obstetrics and Gynecology, Verona, Italy
31University of Insubria, Gynecologic Oncology Unit, Varese, Italy
32European Institute of Oncology, Milan, Italy
33University of Florence, Department of Obstetrics and Gynecology, Lucca, Italy
34University of Pisa, Department of Obstetrics and Gynecology, Pisa, Italy
35National University of Singapore, Department of Obstetrics and Gynecology, Singapore, Republic of
36Hospital of Turin, Department of Obstetrics and Gynecology, Turin, Italy
37University of Verona, Department of Obstetrics and Gynecology, Verona, Italy

**Introduction** Sentinel-lymph node biopsy has safely replaced lymphadenectomy in the staging of many solid cancers. The aim of this study was to evaluate the sensitivity and specificity of sentinel-lymph-node mapping compared with the gold standard of complete lymphadenectomy in detecting metastatic disease for early stage ovarian cancer.

**Methods** In the SELLY multicentre, prospective, phase II trial (EUDRACT 2019–001088-38) patients with presumed stage I-II epithelial ovarian cancer and planned for immediate or delayed minimally-invasive comprehensive staging were eligible for study inclusion. Patients received an injection of indocyanine green and sentinel-lymph-node mapping followed by pelvic and para-aortic lymphadenectomy. Seven centers from 5 in Italy participated in the trial. Negative sentinel lymph nodes (by haematooxylin and eosin staining on sections) were ultra-staged with immunohistochemistry for cytokertain. The primary endpoint, sensitivity of the sentinel-lymph-node-based detection of metastatic disease, was defined as the proportion of patients with node-positive disease with successful sentinel-lymph-node mapping who had metastatic disease correctly identified in the sentinel lymph node.

**Current Trial Status** Between March 2018 and July 2022, 176 patients were enrolled but only 174 received complete study interventions. 100 (58%) patients had successful mapping of at least one sentinel lymph node and 15 of them (15.0%) had positive nodes. Of the latter, 11 of 15 (73.3%) patients had a correct identification of the disease in the SLN. In detail, 7 out of 11 patients required ultrastaging protocol. 4 patients with node-positive disease had a negative SLN. Enrollment was closed on January 2023. Data analysis is about to be completed.

**TP023/#61**

**AN PROSPECTIVE, SINGLE-ARM, PHASE II STUDY OF ALTERNATING REGIMENS OF FLUZOPARIB AND ORAL ETOPOSIDE MAINTENANCE THERAPY, IN NEWLY DIAGNOSED ADVANCED OVARIAN CANCER: FARE TRIAL**

Yongpeng Wang*, 1Rui Tong, Xueimei Li, Weiwei Tang, Tingting Yu, Jia Liu, Chunyan Wang, Cancer Hospital of ChifMedical University, Liaoning Cancer Hospital and Institute, Department of Gynecology, Shenyang, China

10.1136/ijgc-2023-IGCS.483

**Introduction** Most patients with ovarian cancer (OC) are diagnosed in advanced stages. A current therapy option for advanced OC patients is debulking surgery; followed by platinum-based chemotherapy ± bevacizumab; followed by maintenance therapy with bevacizumab or monotherapy with PARP inhibitors. The expense of OC maintenance therapy might be substantial. However, the potential benefits of alternating regimens of PARP inhibitors and chemotherapy have not yet been explored. In the alternating regimens of fluzoparib and oral etoposide, both drugs function by directly targeting the DNA of tumour cells. Additionally, the adverse effects of each treatment may be controlled separately without any additive effects. The FARE trial aims to evaluate the efficacy and safety of alternating regimens maintenance therapy in Chinese patients with newly diagnosed advanced OC who are not at high risk of recurrence.

**Methods** The FARE trial is a single-center, investigator-initiated, single-arm, phase II trial of patients with FIGO stage III-IV high grade serous or high grade endometrioid OC. This study includes patients with tumors sample had to be available for central testing to determine BRCA mutation status and homologous-recombination deficiency (HRD) status, no visible residual tumor after primary cytoreductive surgery, and responses to the postoperative platinum-based combination chemotherapy. All enrolled patients are treated with this alternating regimens maintenance therapy for 24 months, until disease progression or unacceptable toxicity, or withdrawal of patient consent. Primary endpoint is progression-free survival (PFS).

**Current Trial Status** Trial in progress: there are no available results at the time of submission, and there are no available conclusions at the time of submission.

**TP024/#1560**

**STANDARD OF CARE THERAPY WITH OR WITHOUT STEREOTACTIC ABLATIVE RADIATION THERAPY FOR RECURRENT OVARIAN CANCER (SABR-ROC): A PROSPECTIVE RANDOMIZED PHASE III TRIAL (KGOG 3064/KROG 2204)**

1Chan Woo Wee*, 2So-Jin Shin, 3Jae Hong No, 4Keun Ho Lee, 5Myoung Cheol Lim, 6Jae-Weon Kim, 7Won Kyung Cho, 8Min Sun Kyung, 9Jae Yoon Sung, 10Jung Kyun Min, 11Eun Ji Lee, 12Seob Jeon, 13Jae-Hoon Kim, 14Young Seok Kim, 15I-Won Roh, 16Jong Hoon Lee, 17Youngmin Choi, 18Hyun Ju Kim, 19Yang Hwan Kim, 20Yong Bae Kim.

1Yonsei Cancer Center, Department of Radiation Oncology, Seoul, Korea, Republic of; 2Keimyung University School of Medicine, Department of Obstetrics and Gynecology, Daegu, Korea, Republic of; 3Seoul National University Bundang Hospital, Department of Obstetrics and Gynecology, Seongnam, Korea, Republic of; 4Seoul St. Mary’s Hospital, Obstetrics and Gynecology, Seoul, Korea, Republic of; 5Center for Gynecologic Cancer, National Cancer Center, Department of Obstetrics and Gynecology, Goyang, Korea, Republic of; 6Seoul National University Hospital, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 7Samsung Medical Center, Department of Radiation Oncology, Seoul, Korea, Republic of; 8Hallym University Kangtan Sacred Heart Hospital, Department of Obstetrics & Gynecology, Hwaseong, Korea, Republic of; 9Korea University Anam Hospital, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 10Korea University Ansan Hospital, Department of Obstetrics and Gynecology, Ansan, Korea, Republic of; 11Department of Obstetrics and Gynecology, Chung-ang University Hospital, Seoul, Korea, Republic of; 12Seonchunhyang University Cheonan Hospital, Department of Obstetrics and Gynecology, Chunan, Korea, Republic of; 13Gangnam Severance Hospital, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 14Asan Medical Center, Department of Radiation Oncology, Seoul, Korea, Republic of; 15CHA Ilsan Medical Center, Department of Obstetrics and Gynecology, Goyang, Korea, Republic of; 16Seoul St. Vincent’s Hospital, Department of Radiation Oncology, Suwon, Korea, Republic of; 17Seoul National University Hospital, Department of Radiation Oncology, Chung-Ang University School of Medicine, Department of Radiation Oncology, Busan, Korea, Republic of; 18Gachon University Gil Hospital, Department of Radiation Oncology, Incheon, Korea, Republic of; 19Ewha Womans University College of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of;

10.1136/ijgc-2023-IGCS.484